Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith A Aberg

Showing results (91-100 of 211) with videos related to

Pageof 22
Sort By:
Clinical Transplantation|September 12, 2020
Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: Experience at large transplant center in New York CityFarah Rahman, Sean T H Liu, Sarah Taimur, et al.
Journal of Clinical Lipidology|April 11, 2017
Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275)Daniel E Nixon, Ronald J Bosch, Ellen S Chan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 28, 2018
Human Immunodeficiency Virus (HIV) Viral Suppression After Transition From Having No Healthcare Coverage and Relying on Ryan White HIV/AIDS Program Support to Medicaid or Private Health InsuranceJulia Raifman, Keri Althoff, Peter F Rebeiro, et al.
AIDS (London, England)|May 25, 2010
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206Marisa Tungsiripat, Douglas Kitch, Marshall J Glesby, et al.
Frontiers in Sociology|June 7, 2021
Chronic High Risk Prescription Opioid Use Among Persons With HIVAna Ventuneac, Gavriella Hecht, Emily Forcht, et al.
Antimicrobial Agents and Chemotherapy|August 17, 2002
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV sheddingJacob P Lalezari, Judith A Aberg, Laurene H Wang, et al.
Ebiomedicine|February 15, 2023
Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin interventionJesmond Dalli, Douglas Kitch, Meagan P O'Brien, et al.
AIDS (London, England)|July 21, 2017
Oral shedding of herpesviruses in HIV-infected patients with varying degrees of immune statusDirk P Dittmer, Kristen Tamburro, Huichao Chen, et al.
AIDS (London, England)|March 3, 2017
Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIVMabel Toribio, Kathleen V Fitch, Laura Sanchez, et al.
The Journal of Infectious Diseases|March 28, 2003
A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study TeamJudith A Aberg, Paige L Williams, Tun Liu, et al.
Pageof 22

Showing results (91-100 of 211) with videos related to

Sort By:
Pageof 22
Clinical Transplantation|September 12, 2020
Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: Experience at large transplant center in New York CityFarah Rahman, Sean T H Liu, Sarah Taimur, et al.
Journal of Clinical Lipidology|April 11, 2017
Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275)Daniel E Nixon, Ronald J Bosch, Ellen S Chan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 28, 2018
Human Immunodeficiency Virus (HIV) Viral Suppression After Transition From Having No Healthcare Coverage and Relying on Ryan White HIV/AIDS Program Support to Medicaid or Private Health InsuranceJulia Raifman, Keri Althoff, Peter F Rebeiro, et al.
AIDS (London, England)|May 25, 2010
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206Marisa Tungsiripat, Douglas Kitch, Marshall J Glesby, et al.
Frontiers in Sociology|June 7, 2021
Chronic High Risk Prescription Opioid Use Among Persons With HIVAna Ventuneac, Gavriella Hecht, Emily Forcht, et al.
Antimicrobial Agents and Chemotherapy|August 17, 2002
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV sheddingJacob P Lalezari, Judith A Aberg, Laurene H Wang, et al.
Ebiomedicine|February 15, 2023
Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin interventionJesmond Dalli, Douglas Kitch, Meagan P O'Brien, et al.
AIDS (London, England)|July 21, 2017
Oral shedding of herpesviruses in HIV-infected patients with varying degrees of immune statusDirk P Dittmer, Kristen Tamburro, Huichao Chen, et al.
AIDS (London, England)|March 3, 2017
Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIVMabel Toribio, Kathleen V Fitch, Laura Sanchez, et al.
The Journal of Infectious Diseases|March 28, 2003
A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study TeamJudith A Aberg, Paige L Williams, Tun Liu, et al.
Pageof 22